Kidney impairment or congestive heart failure (ibuprofen)
When combined with your IBS subtype, symptom history, and current medications, this genetic information can support a more nuanced conversation about dosing strategy, monitoring expectations, and risk mitigation
Key results from Calocurbs fourth human clinical study include the following: Calocurb is clinically shown to improve body composition by reducing body fat without losing muscle mass Average weight loss of 8.3 lbs (3.77 kg) after six months, compared to 0.88 lbs (0.4 kg) with the placebo group Over 6.5x greater reduction in body fat vs placebo Average body fat loss of 9.9 lbs (4.49 kg) vs 1.5 lbs (0.68 kg) after six months of consistent use of Calocurb vs placebo 3.5x greater reduction in visceral fat vs placebo Average visceral fat loss of 5 in 2 (32.5 cm2) vs 1.4 in 2 (9.1 cm2) lost after six months of consistent use of Calocurb vs placebo For over a decade, Calocurb has undertaken ground-breaking clinical research into Amarasate to continue bringing natural weight management solutions to those interested in GLP-1 and weight loss options
But for most, he says, there's an element of negative reinforcement
Both medications can cause low blood sugar (hypoglycemia), particularly if combined with other glucose-lowering medications, but this risk is generally low when used alone
With physician oversight and individualized treatment planning, medical weight loss becomes a reliable pathway to meaningful, lasting improvement for patients at any stage of their weight loss journey
